Increased urinary angiotensin-converting enzyme 2 in renal transplant patients with diabetes
Fengxia Xiao, Swapnil Hiremath, Greg Knoll, Joseph Zimpelmann, Kajenny Srivaratharajah, Deepak Jadhav, Dean Fergusson, Chris R J Kennedy, Kevin D Burns, Fengxia Xiao, Swapnil Hiremath, Greg Knoll, Joseph Zimpelmann, Kajenny Srivaratharajah, Deepak Jadhav, Dean Fergusson, Chris R J Kennedy, Kevin D Burns
Abstract
Angiotensin-converting enzyme 2 (ACE2) is expressed in the kidney and may be a renoprotective enzyme, since it converts angiotensin (Ang) II to Ang-(1-7). ACE2 has been detected in urine from patients with chronic kidney disease. We measured urinary ACE2 activity and protein levels in renal transplant patients (age 54 yrs, 65% male, 38% diabetes, n = 100) and healthy controls (age 45 yrs, 26% male, n = 50), and determined factors associated with elevated urinary ACE2 in the patients. Urine from transplant subjects was also assayed for ACE mRNA and protein. No subjects were taking inhibitors of the renin-angiotensin system. Urinary ACE2 levels were significantly higher in transplant patients compared to controls (p = 0.003 for ACE2 activity, and p≤0.001 for ACE2 protein by ELISA or western analysis). Transplant patients with diabetes mellitus had significantly increased urinary ACE2 activity and protein levels compared to non-diabetics (p<0.001), while ACE2 mRNA levels did not differ. Urinary ACE activity and protein were significantly increased in diabetic transplant subjects, while ACE mRNA levels did not differ from non-diabetic subjects. After adjusting for confounding variables, diabetes was significantly associated with urinary ACE2 activity (p = 0.003) and protein levels (p<0.001), while female gender was associated with urinary mRNA levels for both ACE2 and ACE. These data indicate that urinary ACE2 is increased in renal transplant recipients with diabetes, possibly due to increased shedding from tubular cells. Urinary ACE2 could be a marker of renal renin-angiotensin system activation in these patients.
Conflict of interest statement
Competing Interests: The authors have declared that no competing interests exist.
Figures
References
- Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9. Circ Res. 2000;87:1–9.
- Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, et al. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem. 2000;275:33238–33243.
- Li N, Zimpelmann J, Cheng K, Wilkins JA, Burns KD. The role of angiotensin converting enzyme 2 in the generation of angiotensin 1–7 by rat proximal tubules. Am J Physiol Renal Physiol. 2005;288:353–362.
- Shaltout HA, Westwood BM, Averill DB, Ferrario CM, Figueroa JP, et al. Angiotensin metabolism in renal proximal tubules, urine, and serum of sheep: evidence for ACE2-dependent processing of angiotensin II. Am J Physiol Renal Physiol. 2007;292:82–91.
- Ye M, Wysocki J, Naaz P, Salabat MR, LaPointe MS, et al. Increased ACE 2 and decreased ACE protein in renal tubules from diabetic mice: a renoprotective combination? Hypertension. 2004;43:1120–1125.
- Oudit GY, Herzenberg AM, Kassiri Z, Wong D, Reich H, et al. Loss of angiotensin-converting enzyme-2 leads to the late development of angiotensin II-dependent glomerulosclerosis. Am J Pathol. 2006;168:1808–1820.
- Wong DW, Oudit GY, Reich H, Kassiri Z, Zhou J, et al. Loss of angiotensin-converting enzyme-2 (Ace2) accelerates diabetic kidney injury. Am J Pathol. 2007;171:438–451.
- Wysocki J, Ye M, Rodriguez E, González-Pacheco FR, Barrios C, et al. Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension. Hypertension. 2010;55:90–98.
- Oudit GY, Liu GC, Zhong J, Basu R, Chow FL, et al. Human recombinant ACE2 reduces the progression of diabetic nephropathy. Diabetes. 2010;59:529–538.
- Warner FJ, Lew RA, Smith AI, Lambert DW, Hooper NM, et al. Angiotensin-converting enzyme 2 (ACE2), but not ACE, is preferentially localized to the apical surface of polarized kidney cells. J Biol Chem. 2005;47:39353–39362.
- Iwata M, Silva Enciso JE, Greenberg BH. Selective and specific regulation of ectodomain shedding of angiotensin-converting enzyme 2 by tumor necrosis factor alpha-converting enzyme. Am J Physiol Cell Physiol. 2009;297:1318–1329.
- Lambert DW, Yarski M, Warner FJ, Thornhill P, Parkin ET, et al. Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J Biol Chem. 2005;280:30113–30119.
- Jia HP, Look DC, Tan P, Shi L, Hickey M, et al. Ectodomain shedding of angiotensin converting enzyme 2 in human airway epithelia. Am J Physiol Lung Cell Mol Physiol. 2009;297:84–96.
- Mizuiri S, Aoki T, Hemmi H, Arita M, Sakai K, et al. Urinary ACE2 in patients with CKD. Nephrology (Carlton) 2011;16:567–572.
- Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Annal Int Med. 2006;145:247–254.
- Dilauro M, Robertson S, Genest D, Burns KD. The effect of ACE2 and angiotensin-(1–7) in a mouse model of early chronic kidney disease. Am J Physiol Renal Physiology. 2010;298:1523–1532.
- Hermann K, Rittweger R, Phillips MI, Ring J. Presence of angiotensin peptides in human urine. Clin Chem. 1992;38:1768–1772.
- Casarini DE, Plavinik FL, Zanella MT, Marson O, Krieger JE, et al. Angiotensin converting enzymes from human urine of mild hypertensive untreated patients resemble the N-terminal fragment of human angiotensin I-converting enzyme. Int J Biochem Cell Biol. 2001;33:75–85.
- Su Z, Zimpelmann J, Burns KD. Angiotensin-(1–7) inhibits angiotensin II-stimulated phosphorylation of MAP kinases in proximal tubular cells. Kidney Int. 2006;69:2212–2218.
- Koitka A, Cooper ME, Thomas MC, Tikellis C. Angiotensin converting enzyme 2 in the kidney. Clin Exp Pharmacol Physiol. 2008;35:420–425.
- Leehey DJ, Singh AK, Bast JP, Sethupathi P, Singh R. Glomerular renin angiotensin system in streptozotocin diabetic and Zucker diabetic fatty rats. Transl Res. 2008;151:208–216.
- Reich HN, Oudit GY, Penninger JM, Scholey JW, Herzenberg AM. Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease. Kidney Int. 2008;74:1610–1616.
- Ji H, Menini S, Zheng W, Pesce C, Wu X, et al. Role of angiotensin-converting enzyme 2 and angiotensin(1–7) in 17beta-oestradiol regulation of renal pathology in renal wrap hypertension in rats. Exp Physiol. 2008;93:648–657.
- Wang G, Lai FM, Lai KB, Chow KM, Kwan CH, et al. Urinary mRNA expression of ACE and ACE2 in human type 2 diabetic nephropathy. Diabetologia. 2008;51:1062–1067.
- Lautrette A, Li S, Alili R, Sunnarborg SW, Burtin M, et al. Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach. Nature Med. 2005;8:867–874.
- Melenhorst WB, Visser L, Timmer A, van den Heuvel MC, Stegeman CA, et al. ADAM17 upregulation in human renal disease: a role in modulating TGF-alpha availability? Am J Physiol Renal Physiol. 2009;297:781–790.
- Gonzales PA, Pisitkun T, Hoffert JD, Tchapyjnikov D, Star RA, et al. Large-scale proteomics and phosphoproteomics of urinary exosomes. J Am Soc Nephrol. 2009;20:363–379.
- Mezzano S, Droguett A, Burgos ME, Ardiles LG, Flores CA, et al. Renin-angiotensin system activation and interstitial inflammation in human diabetic nephropathy. Kidney. 2003;Int(Suppl 86: ):64–70.
Source: PubMed